While no anti‐IFNγ therapy has been tested in humans so far, some studies using antibodies against this cytokine have shown some successes in interfering with cancer‐induced muscle loss in mice (Langstein et al, 1991; Matthys et al, 1991). This evidence concerns the gene IFNG and cancer.